« Return to News | CROs/Service Providers

WuXi Posts Another Strong Quarter

Wednesday, August 12, 2009 06:39 AM

Chinese contract research organization (CRO) WuXi PharmaTech reported another quarter of profit growth with a 7% increase compared to the same period last year despite a drop in revenues.

WuXi’s second-quarter 2009 gross profit grew to $27.1 million, up from $25.4 million in the second quarter 2008. Net revenues for the quarter decreased 3% from Q2 2008 to $67 million, due to a 69% drop in revenues in the CRO’s manufacturing services division. This decrease was partially offset by 19% growth in the laboratory services unit—the result of stronger demand for WuXi’s drug discovery and development services. According to the company, the majority of the drop in manufacturing services comes from large projects in 2008 that did not recur in 2009.

Based on the CRO’s financial performance in the second quarter, WuXi reiterated its full-year 2009 guidance to be $265 million to $275 million and increased its full-year 2009 adjusted EBITDA estimate from $72 million to the range of $80 to $85 million.

"WuXi PharmaTech's overall financial performance in the second quarter exceeded our expectations, both in revenues and profitability, building confidence that we will meet our previously announced guidance for revenues and beat our previously announced guidance for adjusted EBITDA for the full year," said chairman and CEO Dr. Ge Li in a statement. "The company is achieving its current financial goals in a difficult operating environment while investing in new growth opportunities that we expect will drive revenue and income growth over the next several years.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.